Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enliven TherapeuticsELVN -1.43%31 Buyback Yield % is 0.00 as of Aug. 13, 2026. GuruFocus rates ELVN with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 725 Biotechnology companies, Enliven Therapeutics ranks worse than 137930.9% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Enliven Therapeutics Buyback Yield % Related Terms
Enliven Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Enliven Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELVN vs PBLS, CPRX, DNLI: Buyback Yield % Comparison
For the Biotechnology subindustry, Enliven Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics (ELVN) has a Buyback Yield % of 0.00 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Enliven Therapeutics and its competitors. According to the industry distribution chart, Enliven Therapeutics ranks #999999 out of 725 companies in the Biotechnology industry.
Is Enliven Therapeutics' Buyback Yield % too high?
Enliven Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Enliven Therapeutics ranks #999999 out of 725 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' Buyback Yield % compare to PBLS and CPRX?
According to the Biotechnology industry distribution chart, Enliven Therapeutics ranks #999999 out of 725 companies for Buyback Yield %. This places Enliven Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Enliven Therapeutics and its competitors. Enliven Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current Buyback Yield % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score
Get the complete analysis for ELVN
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELVN has been successfully added to your 
